Trials / Completed
CompletedNCT00675194
Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
A Prospective, Open, Comparative Multicentre Phase II Study for the Evaluation of Irinotecan and Capecitabine Versus Cisplatin and Capecitabine in Advanced Gastric Adenocarcinoma or Gastric-Oesophagal Junction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Johannes Gutenberg University Mainz · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine which Arm (capecitabine + irinotecan versus capecitabine + cisplatin) shows higher response rates in the treatment of advanced gastric-oesophagal cancer Furthermore, comparison of progression-free survival, 1-year survival, Quality of Life and safety
Detailed description
capecitabine + irinotecan versus capecitabine + cisplatin, as published by Kang et al. (ASCO 2006)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin, Irinotecan, Capecitabine |
Timeline
- Start date
- 2003-10-01
- Completion
- 2007-10-01
- First posted
- 2008-05-08
- Last updated
- 2008-05-20
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00675194. Inclusion in this directory is not an endorsement.